Trial Profile
A Randomized, Open Label, Multiple Dose, Parallel Group Study to Assess the Safety and Pharmacokinetic Comparability of Two VAY736 Drug Products in Patients With Rheumatoid Arthritis
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 25 Jan 2024
Price :
$35
*
At a glance
- Drugs Ianalumab (Primary) ; Ianalumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 19 Jan 2024 Planned End Date changed from 21 Aug 2024 to 18 Jul 2024.
- 19 Jan 2024 Planned primary completion date changed from 21 Aug 2024 to 18 Jul 2024.
- 31 Aug 2023 Planned End Date changed from 2 Oct 2024 to 21 Aug 2024.